Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Clinical Therapeutics

• Publication date

  2012-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clinthera.2012.06.010PMID 22749259
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Update on the role of antipsychotics in the treatment of Tourette syndrome

  2012cited by this paper
• Effect of tetrabenazine on computerized dynamic posturography in Huntington disease patients.

  2012cited by this paper
• Tetrabenazine treatment for stereotypies and tics associated with dementia.

  2012cited by this paper
• Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors.

  2011cited by this paper
• Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders

  2011cited by this paper
• Tetrabenazine for the Treatment of Tardive Dyskinesia

  2011cited by this paper
• Use of Tetrabenazine in Huntington Disease Patients on Antidepressants or with Advanced Disease: Results from the TETRA-HD Study

  2011cited by this paper
• Tetrabenazine

  2011cited by this paper
• Vesicular monoamine transporters: Structure‐function, pharmacology, and medicinal chemistry

  2011cited by this paper
• Pearls: Hyperkinetic Movement Disorders

  2010cited by this paper
• Advances in the Pharmacological Management of Huntington’s Disease

  2010cited by this paper
• Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.

  2010cited by this paper
• Role of Tetrabenazine for Huntington's Disease-Associated Chorea

  2010cited by this paper
• Treatment strategies for dystonia

  2010cited by this paper
• Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease

  2010cited by this paper
• Therapeutic interventions for symptomatic treatment in Huntington's disease.

  2009cited by this paper
• Tetrabenazine

  2009cited by this paper
• Increased oxidative stress in patients with amyotrophic lateral sclerosis/Parkinsonism‐dementia complex in the Kii peninsula, Japan

  2009cited by this paper
• Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators

  2009cited by this paper
• The Long-term Effect of Tetrabenazine in the Management of Huntington Disease

  2008cited by this paper
• A Study of Chorea After Tetrabenazine Withdrawal in Patients With Huntington Disease

  2008cited by this paper
• Falls and gait disturbances in Huntington's disease

  2008cited by this paper
• Tourette’s Syndrome and Role of Tetrabenazine

  2008cited by this paper
• Huntington’s disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases

  2008cited by this paper
• Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome.

  2008cited by this paper
• Short‐term effects of tetrabenazine on chorea associated with Huntington's disease

  2007cited by this paper
• Practice Advisory: Utility of surgical decompression for treatment of diabetic neuropathy: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

  2007cited by this paper
• Mechanisms of Disease: basic-research-driven investigations in humans—the case of hyperkinetic disorders

  2007cited by this paper
• Autopsy‐proven Huntington's disease with 29 trinucleotide repeats

  2007cited by this paper
• Tetrabenazine in the treatment of Tourette syndrome

  2007cited by this paper
• Tardive Dyskinesia

  2007cited by this paper
• A systematic review of the treatment studies in Huntington’s disease since 1990

  2007cited by this paper
• Long‐term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders

  2007cited by this paper
• Pharmacological management of Huntington's disease: an evidence-based review.

  2006cited by this paper
• Tetrabenazine therapy of pediatric hyperkinetic movement disorders

  2006cited by this paper
• Is History of Depression a Contraindication to Treatment With Tetrabenazine?

  2006cited by this paper
• Tetrabenazine as antichorea therapy in Huntington disease

  2006cited by this paper
• Tetrabenazine for hyperglycemic‐induced hemichorea–hemiballismus

  2006cited by this paper
• Seminar on choreas.

  2006cited by this paper
• Drug-Induced Diseases: Prevention, Detection, and Management

  2005cited by this paper
• Tetrabenazine Treatment in Movement Disorders

  2004cited by this paper
• The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders

  2004cited by this paper
• Profile of cognitive progression in early Huntington’s disease

  2003cited by this paper
• Diagnosis of Huntington disease.

  2003cited by this paper
• Progression of symptoms in the early and middle stages of Huntington disease.

  2001cited by this paper
• Bruxism in Huntington's disease

  2000cited by this paper
• Neuropsychiatry of Huntington's disease and other basal ganglia disorders.

  2000cited by this paper
• DNA analysis of Huntington’s disease

  1999cited by this paper
• Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol.

  1999cited by this paper
• Assessment of Extrastriatal Vesicular Monoamine Transporter Binding Site Density Using Stereoisomers of [11C]Dihydrotetrabenazine

  1999cited by this paper
• Dystonia in Huntington's disease: Prevalence and clinical characteristics

  1999cited by this paper
• Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia

  1998cited by this paper
• A case of tetrabenazine‐induced neuroleptic malignant syndrome after prolonged treatment

  1997cited by this paper
• Long-term effects of tetrabenazine in hyperkinetic movement disorders

  1997cited by this paper
• Equilibrium versus Compartmental Analysis for Assessment of the Vesicular Monoamine Transporter Using (+)-α-[11C]Dihydrotetrabenazine (DTBZ) and Positron Emission Tomography

  1997cited by this paper
• Executive and mnemonic functions in early Huntington's disease.

  1996cited by this paper
• Tetrabenazine as a cause of neuroleptic malignant syndrome

  1996cited by this paper
• Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats.

  1996cited by this paper
• In vivo imaging of the brain vesicular monoamine transporter.

  1995cited by this paper
• Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease.

  1995cited by this paper
• Tourettism associated with Huntington's disease

  1995cited by this paper
• Huntington's Disease: Update and Review of Neuropsychiatric Aspects

  1994cited by this paper
• Psychopathology in Huntington's disease patients

  1994cited by this paper
• In Vivo Imaging of Vesicular Monoamine Transporters in Human Brain Using [11C]Tetrabenazine and Positron Emission Tomography

  1993cited by this paper
• Adult onset myoclonic Huntington's disease

  1993cited by this paper
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

  1993cited by this paper
• Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease.

  1992cited by this paper
• Causes of death in patients with Huntington's disease and in unaffected first degree relatives.

  1992cited by this paper
• Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease.

  1991cited by this paper
• Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport.

  1988cited by this paper
• Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease.

  1988cited by this paper
• Conditions associated with Huntington's disease at death. A case-control study.

  1988cited by this paper
• Treatment of Tardive Dyskinesia: Preliminary Report on Use of Tetrabenazine

  1988cited by this paper
• Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias

  1988cited by this paper
• Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies.

  1987cited by this paper
• Motor, Behavioral and Pharmacologic Findings in Tourette's Syndrome

  1987cited by this paper
• Mechanism of transport and storage of neurotransmitters.

  1987cited by this paper
• Mechanism of Transport and Storage of Neurotransmitter

  1987cited by this paper
• Segmental myoclonus. Clinical and pharmacologic study.

  1986cited by this paper
• Selective sparing of a class of striatal neurons in Huntington's disease.

  1985cited by this paper
• Increased rate of suicide among patients with Huntington's disease.

  1984cited by this paper
• Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome

  1984cited by this paper
• The treatment of severe dystonia in children and adults.

  1984cited by this paper
• Psychiatric syndromes in Huntington's disease.

  1983cited by this paper
• Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.

  1983cited by this paper
• Abnormal ocular motor control in Huntington's disease

  1983cited by this paper
• Treatment of hyperkinetic movement disorders with tetrabenazine: A double‐blind crossover study

  1982cited by this paper
• Tetrabenazine and movement disorders

  1981cited by this paper
• Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Effects of alpha methyl para tyrosine and tetrabenazine.

  1974cited by this paper
• Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine.

  1973cited by this paper
• Long-Term Treatment of Tardive Dyskinesia with Haloperidol and Tetrabenazine

  1973cited by this paper
• Treatment of involuntary movement disorders with tetrabenazine

  1972cited by this paper
• Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine.

  1972cited by this paper
• Persistent Phenothiazine Dyskinesia Treated with Tetrabenazine

  1971cited by this paper
• Benzoquinolizine Derivatives: a New Class of Monamine Decreasing Drugs With Psychotropic Action

  1962cited by this paper
• Open Access Full Text Article Management of Huntington’s disease: role of tetrabenazine Review

  year unknowncited by this paper

• Real-World Experiences with VMAT2 Inhibitors in Pediatric Hyperkinetic Movement Disorders

  2025cites this paper
• Impact of Postural Restrictions on Tetrabenazine Pharmacokinetics in Healthy Volunteers: A Randomized Crossover Study Emphasizing Variance Minimization Strategies in Good Clinical Practice-Guided Bioequivalence Research

  2025cites this paper
• Impact of brief maternal separation on rodent models of anergia induced by dopamine depletion: analysis in mice of both sexes during adulthood.

  2025cites this paper
• Deciphering Ibogaine’s Matrix Pharmacology: Multiple Transporter Modulation at Serotonin Synapses

  2025cites this paper
• Application of separation and configuration identification of the four tetrabenazine stereoisomers in determining their pharmacokinetics

  2025cites this paper
• Different treatment methods for tics and Tourette Syndrome

  2025cites this paper
• Effort-related motivational effects of methylphenidate: Reversal of the low-effort bias induced by tetrabenazine and enhancement of progressive ratio responding in male and female rats.

  2025cites this paper
• An Open‐Label Pilot Study to Examine the Safety, Tolerability and Efficacy of Deutetrabenazine in Isolated Dystonia

  2025cites this paper
• Thermoreversible Ionogel for Enhanced Nose-to-brain Delivery of Tetrabenazine Hydrochloride: Optimization by Central Composite Design and In Vitro Ex Vivo Evaluation

  2025cites this paper
• Physician experience and perceptions of tetrabenazine for the treatment of tardive dyskinesia and Huntington’s chorea: a survey of neurologists and psychiatrists

  2025cites this paper
• Vesicular monoamine transport inhibitors: current uses and future directions.

  2025cites this paper
• Exploring the Role of Deutetrabenazine in the Treatment of Chorea Linked with Huntington's Disease.

  2024cites this paper
• Structural mechanisms for VMAT2 inhibition by tetrabenazine

  2024cites this paper
• Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington’s disease

  2024cites this paper
• Późne dyskinezy polekowe — rekomendacje grupy ekspertów: aktualizacja 2024

  2024influential citation
• Pharmacological characterization of sex differences in the effects of dopaminergic drugs on effort-based decision making in rats

  2024cites this paper
• Symptomatic Treatment of Extrapyramidal Hyperkinetic Movement Disorders

  2024cites this paper
• Engineering of a mammalian VMAT2 for cryo-EM analysis results in non-canonical protein folding

  2024cites this paper
• VALIDATED REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR THE ESTIMATION OF TETRABENAZINE IN SELF-NANO EMULSIFYING DRUG DELIVERY SYSTEMS

  2024cites this paper
• Neuroleptic malignant syndrome in Huntington disease

  2024cites this paper
• Tetrabenazine, a vesicular monoamine transporter 2 inhibitor, inhibits vesicular storage capacity and release of monoamine transmitters in mouse brain tissue

  2024cites this paper
• [Tardive dyskinesia].

  2023cites this paper
• Transport and inhibition mechanisms of human VMAT2

  2023cites this paper
• Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2

  2023cites this paper
• The Neurobiology of Activational Aspects of Motivation: Exertion of Effort, Effort-Based Decision Making, and the Role of Dopamine.

  2023cites this paper
• Assessment of the triple reuptake inhibitor diclofensine: effort-Assessment of the triple reuptake inhibitor diclofensine: effort-based decision-making in a rodent model of motivational based decision-making in a rodent model of motivational dysfunction dysfunction

  2023cites this paper
• Structural mechanisms for VMAT2 inhibition by tetrabenazine

  2023cites this paper
• Valbenazine promotes body growth via growth hormone signaling during zebrafish embryonic development.

  2023cites this paper
• Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles

  2023cites this paper
• Movement disorders of the mouth: a review of the common phenomenologies

  2022cites this paper
• Vigor, Effort-Related Aspects of Motivation and Anhedonia.

  2022cites this paper
• Effects of the dopamine depleting agent tetrabenazine on detailed temporal parameters of effort-related choice responding.

  2022cites this paper
• Complexities and Paradoxes in Understanding the Role of Dopamine in Incentive Motivation and Instrumental Action: Exertion of Effort vs. Anhedonia.

  2022cites this paper
• A Pragmatic Approach to Assessment of Chronic and Recurrent Pain in Children with Severe Neurologic Impairment

  2022cites this paper
• Critical review of RDoC approaches to the study of motivation with animal models: effort valuation/willingness to work.

  2022cites this paper
• Impact of Fluoxetine on Behavioral Invigoration of Appetitive and Aversively Motivated Responses: Interaction With Dopamine Depletion

  2021cites this paper
• Effective Treatment of Dystonia with Deep Brain Stimulation and Tetrabenazine in Pantothenate Kinase-Associated Neurodegeneration: A Case Report

  2021cites this paper
• Case Report: Valbenazine as a Treatment for Tardive Dyskinesia and Unexpected Antipsychotic Effects.

  2021cites this paper
• Dystonias

  2021cites this paper
• Sex differences in lever pressing and running wheel tasks of effort-based choice behavior in rats: suppression of high effort activity by the serotonin transport inhibitor fluoxetine.

  2021cites this paper
• Perspectives on the pharmacological management of dystonia

  2021cites this paper
• Understanding the Pathophysiology of Tourette’s Syndrome: A Review

  2021cites this paper
• An Efficient Construction of CF 3 ‐Substituted Spirooxindole‐Fused Benzo[a]quinolizidines by a Three‐Component Cyclization

  2021cites this paper
• Energizing effects of bupropion on effortful behaviors in mice under positive and negative test conditions: modulation of DARPP-32 phosphorylation patterns

  2021cites this paper
• Targeting Ubiquitin-Proteasome Pathway by Natural Products: Novel Therapeutic Strategy for Treatment of Neurodegenerative Diseases

  2020cites this paper
• Investigation of the effects of cannabidiol on vacuous chewing movements, locomotion, oxidative stress and blood glucose in rats treated with oral haloperidol

  2020cites this paper
• Revisiting the Abnormal Involuntary Movement Scale: Proceedings From the Tardive Dyskinesia Assessment Workshop

  2020cites this paper
• Synthesis of Tetrabenazine and Its Derivatives, Pursuing Efficiency and Selectivity

  2020cites this paper
• In vitro binding affinity vs. in vivo site occupancy: A PET study of four diastereomers of dihydrotetrabenazine (DTBZ) in monkey brain.

  2020cites this paper
• Preference for Exercise vs. More Sedentary Reinforcers: Validation of an Animal Model of Tetrabenazine-Induced Anergia

  2020cites this paper
• Treatment of tics associated with Tourette syndrome

  2020cites this paper
• Dystonia

  2020cites this paper
• Behavioral and dopamine transporter binding properties of the modafinil analog (S, S)-CE-158: reversal of the motivational effects of tetrabenazine and enhancement of progressive ratio responding

  2020cites this paper
• The dopamine depleting agent tetrabenazine alters effort-related decision making as assessed by mouse touchscreen procedures

  2020influential citation
• VMAT2 inhibitors for the treatment of hyperkinetic movement disorders.

  2020cites this paper
• Pediatric Prevention: Tic Disorders.

  2020cites this paper
• Perceptions of the impact of chorea on health-related quality of life in Huntington disease (HD): A qualitative analysis of individuals across the HD spectrum, family members, and clinicians

  2020cites this paper
• Treatment of Tardive Dyskinesia.

  2020cites this paper
• Exploring the anti-stress effects of imatinib and tetrabenazine in cold-water immersion-induced acute stress in mice

  2020cites this paper
• Pediatric Movement Disorders and Neuromodulation: An Overview

  2020cites this paper
• Spasticity and Dystonia: A Brief Review

  2020cites this paper
• Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation

  2020cites this paper
• The novel atypical dopamine transport inhibitor CT-005404 has pro-motivational effects in neurochemical and inflammatory models of effort-based dysfunctions related to psychopathology.

  2020cites this paper
• Treatment of Movement Disorder Emergencies in Autoimmune Encephalitis in the Neurosciences ICU

  2019cites this paper
• Chorea.

  2019cites this paper
• Role of Vesicular Monoamine Transporter 2 Inhibitors in Tardive Dyskinesia Management

  2019cites this paper
• Behaviour of Tetrabenazine in Acid Medium: Reassessment and Impact on Formulation

  2019cites this paper
• Treatment of Tardive Dystonia

  2019cites this paper
• Tardive Dyskinesia After Aripiprazole Treatment That Improved With Tetrabenazine, Clozapine, and Botulinum Toxin

  2019cites this paper
• Keeping up with the clinical advances: tardive dyskinesia

  2019cites this paper
• Tardive Dystonia due to D2 Antagonists and Other Agents

  2018cites this paper
• Treatment options for chorea

  2018cites this paper
• Reprint of: Clinical management of tardive dyskinesia: Five steps to success

  2018cites this paper
• Current Approaches and New Developments in the Pharmacological Management of Tourette Syndrome

  2018cites this paper
• Genetics of tardive dyskinesia: Promising leads and ways forward.

  2018cites this paper
• Tourette syndrome: a disorder of the social decision-making network

  2018cites this paper
• Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective

  2018cites this paper
• Update on the Pharmacological Treatment of Tics with Dopamine-Modulating Agents.

  2018cites this paper
• Partial reversal of the effort‐related motivational effects of tetrabenazine with the MAO‐B inhibitor deprenyl (selegiline): Implications for treating motivational dysfunctions

  2018cites this paper
• Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.

  2018cites this paper
• Deutetrabenazine for the treatment of Huntington’s chorea

  2018cites this paper
• VMAT2 Inhibitors in Neuropsychiatric Disorders

  2018cites this paper
• Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly

  2018cites this paper
• Standard, Complementary, and Future Treatment Options for Tics

  2018cites this paper
• Substrates of Human CYP2D6

  2018cites this paper
• Metadata of the chapter that will be visualized in SpringerLink

  2017cites this paper
• Caractérisation neurochimique de la dyskinésie tardive dans un modèle primate non humain

  2017cites this paper
• Syndrome de Gilles de la Tourette et thérapeutiques : revue de littérature

  2017cites this paper
• Valbenazine for the treatment of tardive dyskinesia

  2017cites this paper
• Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management

  2017cites this paper
• Clinical management of tardive dyskinesia: Five steps to success.

  2017cites this paper
• Medical management of motor manifestations of Huntington disease.

  2017cites this paper
• Therapeutic Advances in Neurological Disorders

  2017cites this paper
• How Much Do We Know about Adult-onset Primary Tics? Prevalence, Epidemiology, and Clinical Features

  2017cites this paper
• Clinical Management of Dystonia in Childhood

  2017cites this paper
• Globus Pallidus İnfarktı İlişkili Kore: Olgu Sunumu / Chorea Associated with Globus Pallidus Infarction: A Case Report

  2017cites this paper
• Formulation of orodispersible films for paediatric therapy: investigation of feasibility and stability for tetrabenazine as drug model

  2017cites this paper
• Valbenazine for the treatment of tardive dyskinesia

  2017influential citation
• Pharmacogenomics of Neurodegenerative Diseases: Roles in Personalized Medicines

  2017cites this paper
• Orodispersible films based on amorphous solid dispersions of tetrabenazine.

  2017cites this paper